PCSK9: Regulation and target for drug development for dyslipidemia

Annual Review of Pharmacology and Toxicology

Volumn 57, Issue , 2017, Pages 223-244

  Burke, Amy C ^a   Dron, Jacqueline S ^a   Hegele, Robert A ^a   Huff, Murray W ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Cardiovascular disease; Low density lipoprotein cholesterol; Low density lipoprotein receptor; PCSK9 inhibitors; Proprotein convertase subtilisin kexin type 9

Indexed keywords

ADNECTIN DERIVATIVE; ANTILIPEMIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CELL SURFACE RECEPTOR; ENZYME PRECURSOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCLONAL ANTIBODY; PROPROTEIN CONVERTASE 9; PROPROTEIN CONVERTASE 9 INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ENZYME INHIBITOR; PCSK9 PROTEIN, HUMAN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; ENZYME INHIBITION; ENZYME RELEASE; FAMILIAL HYPERCHOLESTEROLEMIA; GAIN OF FUNCTION MUTATION; GENE; GENETIC VARIABILITY; HUMAN; INTERNALIZATION; LOSS OF FUNCTION MUTATION; LYSOSOME; META ANALYSIS (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; PCSK9 GENE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY MECHANISM; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; ENZYMOLOGY; HYPERCHOLESTEROLEMIA; METABOLISM; PHYSIOLOGY; PROCEDURES; TRENDS;

ANIMALS; CHOLESTEROL, LDL; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DYSLIPIDEMIAS; ENZYME INHIBITORS; HUMANS; HYPERCHOLESTEROLEMIA; PROPROTEIN CONVERTASE 9;

EID: 85009060691     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010716-104944     Document Type: Review

References (130)

1. Agarwal SK, Avery CL, Ballantyne CM, Catellier D,Nambi V, et al. 2011. Sources of variability in measurements of cardiac troponinTin a community-based sample: the Atherosclerosis Risk in Communities study. Clin. Chem. 57:891-97
2. Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, et al. 2012. Association of LDL cholesterol, non-HDLcholesterol, and apolipoproteinBlevelswith risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 307:1302-9
3. Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, et al. 2011. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ. Cardiovasc. Qual. Outcomes 4:337-45
4. Genser B, Marz W. 2006. Low density lipoprotein cholesterol, statins and cardiovascular events: a metaanalysis. Clin. Res. Cardiol. 95:393-404
5. Avis HJ,Hutten BA, GagneC, Langslet G, McCrindle BW, et al. 2010. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J. Am. Coll. Cardiol. 55:1121-26
6. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, et al. 2015. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 372:2387-97
7. Needham M, Mastaglia FL. 2014. Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul. Disord. 24:4-15
8. Abifadel M, Rabès JP, Devillers M, Munnich A, Erlich D, et al. 2009. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum. Mutat. 30:520-29
9. Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, et al. 2003. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34:154-56
10. Cohen JC, Boerwinkle E, Mosley TH Jr., Hobbs HH. 2006. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354:1264-72
11. SeidahNG, Awan Z, Chrétien M, Mbikay M. 2014. PCSK9: a key modulator of cardiovascular health. Circ. Res. 114:1022-36
12. Chan JC, Piper DE, Cao Q, Liu D, King C, et al. 2009. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. PNAS 106:9820-25
13. Shimada YJ, Cannon CP. 2015. PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future. Eur. Heart. J. 36:2415-24
14. Seidah NG, Prat A. 2012. The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug Discov. 11:367-83
15. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, et al. 2003. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. PNAS 100:928-33
16. Cunningham D, Danley DE, Geoghegan KF, Griffor MC, Hawkins JL, et al. 2007. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat. Struct. Mol. Biol. 14:413-19
17. Horton JD, Cohen JC, Hobbs HH. 2009. PCSK9: a convertase that coordinates LDL catabolism. J. Lipid Res. 50(Suppl.):S172-97
18. Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, et al. 2004. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 279:48865-75
19. MaxwellKN, Breslow JL. 2004. Adenoviral-mediated expression of Pcsk9 inmice results in a low-density lipoprotein receptor knockout phenotype. PNAS 101:7100-5
20. ParkSW,Moon YA, Horton JD. 2004. Post-transcriptional regulation of lowdensity lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J. Biol. Chem. 279:50630-38
21. Brown MS, Goldstein JL. 1986. A receptor-mediated pathway for cholesterol homeostasis. Science 232:34-47
22. Holla OL, Cameron J, Berge KE, Ranheim T, Leren TP. 2007. Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly. BMC Cell Biol. 8:9
23. Poirier S,Mayer G, Poupon V, McPherson PS, Desjardins R, et al. 2009. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J. Biol. Chem. 284:28856-64
24. Poupon V, Girard M, Legendre-Guillemin V, Thomas S, Bourbonniere L, et al. 2008. Clathrin light chains function in mannose phosphate receptor trafficking via regulation of actin assembly. PNAS 105:168-73
25. Saavedra YG, DayR, SeidahNG. 2012. TheM2module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway. J. Biol. Chem. 287:43492-501
26. Kosenko T, Golder M, Leblond G, Weng W, Lagace TA. 2013. Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation. J. Biol. Chem. 288:8279-88
27. Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, et al. 2008. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J. Biol. Chem. 283:2363-72
28. Shan L, Pang L, Zhang R, Murgolo NJ, Lan H, Hedrick JA. 2008. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. Biochem. Biophys. Res. Commun. 375:69-73
29. Canuel M, Sun X, Asselin MC, Paramithiotis E, Prat A, Seidah NG. 2013. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLOS ONE 8:e64145
30. Roubtsova A, Munkonda MN, Awan Z, Marcinkiewicz J, Chamberland A, et al. 2011. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler. Thromb. Vasc. Biol. 31:785-91
31. Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, et al. 2006. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 79:514-23
32. Bonnefond A, Yengo L, Le May C, Fumeron F, Marre M, et al. 2015. The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis. Diabetologia 58:2051-55
33. Demers A, Samami S, Lauzier B,Des RosiersC, Sock ET, et al. 2015. PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver. Arterioscler. Thromb. Vasc. Biol. 35:2517-25
34. Zaid A, Roubtsova A, Essalmani R,Marcinkiewicz J, Chamberland A, et al. 2008. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 48:646-54
35. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, et al. 2015. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372:1489-99
36. Sabatine MS,Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, et al. 2015. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372:1500-9
37. Labonté P, Begley S, Guévin C, Asselin MC, Nassoury N, et al. 2009. PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. Hepatology 50:17-24
38. Dubuc G, Chamberland A,WassefH,Davignon J, SeidahNG, et al. 2004. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 24:1454-59
39. JeongHJ, LeeHS,KimKS,KimYK,Yoon D, ParkSW.2008. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J. Lipid Res. 49:399-409
40. Horton JD, Goldstein JL, BrownMS. 2002. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Investig. 109:1125-31
41. Browning JD, Horton JD. 2010. Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans. J. Lipid Res. 51:3359-63
42. Persson L, Cao G, Stahle L, Sjoberg BG, Troutt JS, et al. 2010. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler. Thromb. Vasc. Biol. 30:2666-72
43. Horton JD, Cohen JC, Hobbs HH. 2007. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem. Sci. 32:71-77
44. Lagace TA. 2014. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Curr. Opin. Lipidol. 25:387-93
45. LambertG, Jarnoux AL, Pineau T, Pape O, Chetiveaux M, et al. 2006. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor. Endocrinology 147:4985-95
46. Sun H, Samarghandi A, Zhang N, Yao Z, Xiong M, Teng BB. 2012. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler. Thromb. Vasc. Biol. 32:1585-95
47. Li H, Dong B, Park SW, Lee HS, ChenW, Liu J. 2009. Hepatocyte nuclear factor 1plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J. Biol. Chem. 284:28885-95
48. Dong B, Wu M, Li H, Kraemer FB, Adeli K, et al. 2010. Strong induction of PCSK9 gene expression through HNF1 and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J. Lipid Res. 51:1486-95
49. Ai D, Chen C, Han S, Ganda A, Murphy AJ, et al. 2012. Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice. J. Clin. Investig. 122:1262-70
50. Hussain Y, Ding Q, Connelly PW, Brunt JH, Ban MR, et al. 2015. G-protein estrogen receptor as a regulator of low-density lipoprotein cholesterol metabolism: cellular and population genetic studies. Arterioscler. Thromb. Vasc. Biol. 35:213-21
51. Persson L,Henriksson P,Westerlund E,Hovatta O, Angelin B, RudlingM. 2012. Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but not Lp(a) or bile acid synthesis in women. Arterioscler. Thromb. Vasc. Biol. 32:810-14
52. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, et al. 2006. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabioticmice. J. Clin. Investig. 116:2995-3005
53. Denis M, Marcinkiewicz J, Zaid A, Gauthier D, Poirier S, et al. 2012. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation 125:894-901
54. Al-Mashhadi RH, Sørensen CB, Kragh PM, Christoffersen C, Mortensen MB, et al. 2013. Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant. Sci. Transl. Med. 5:166ra1
55. Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, et al. 2005. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. PNAS 102:5374-79
56. Ason B, van der Hoorn JWA, Chan J, Lee E, Pieterman EJ, et al. 2014. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE. J. Lipid Res. 55:2370-79
57. Seidah NG, Poirier S, Denis M, Parker R, Miao B, et al. 2012. Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. PLOS ONE 7:e41865
58. Le May C, Berger JM, Lespine A, Pillot B, Prieur X, et al. 2013. Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1. Arterioscler. Thromb. Vasc. Biol. 33:1484-93
59. Mbikay M, Sirois F, Mayne J, Wang GS, Chen A, et al. 2010. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett. 584:701-6
60. Baass A, Dubuc G, Tremblay M, Delvin EE, O'Loughlin J, et al. 2009. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin. Chem. 55:1637-45
61. Lakoski SG, Lagace TA, Cohen JC,Horton JD, Hobbs HH. 2009. Genetic and metabolic determinants of plasma PCSK9 levels. J. Clin. Endocrinol. Metab. 94:2537-43
62. Richard C, Couture P, Desroches S, Benjannet S, Seidah NG, et al. 2012. Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome. Br. J. Nutr. 107:705-11
63. Costet P, Cariou B, Lambert G, Lalanne F, Lardeux B, et al. 2006. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J. Biol. Chem. 281:6211-18
64. Berge KE, Ose L, Leren TP. 2006. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler. Thromb. Vasc. Biol. 26:1094-100
65. Berthold HK, Seidah NG, Benjannet S, Gouni-Berthold I. 2013. Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels. PLOS ONE 8:e60095
66. Nordestgaard BG, ChapmanMJ, Humphries SE, Ginsberg HN, Masana L, et al. 2013. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. Heart. J. 34:3478-90
67. VarretM, Rabès JP, Saint-Jore B, Cenarro A, Marinoni JC, et al. 1999. A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32. Am. J. Hum. Genet. 64:1378-87
68. Hunt SC, Hopkins PN, Bulka K, McDermott MT, Thorne TL, et al. 2000. Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred. Arterioscler. Thromb. Vasc. Biol. 20:1089-93
69. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. 2005. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37:161-65
70. Kotowski IK, Pertsemlidis A, Luke A, Cooper RS, Vega GL, et al. 2006. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am. J. Hum. Genet. 78:410-22
71. Johansen CT, Hegele RA. 2013. Using Mendelian randomization to determine causative factors in cardiovascular disease. J. Intern. Med. 273:44-47
72. Stender S, Tybjærg-Hansen A. 2016. Using human genetics to predict the effects and side-effects of drugs. Curr. Opin. Lipidol. 27:105-11
73. Abifadel M, Elbitar S, El Khoury P, Ghaleb Y, Chémaly M, et al. 2014. Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs. Curr. Atheroscler. Rep. 16:439
74. Mayne J, Dewpura T, Raymond A, Bernier L, Cousins M, et al. 2011. Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture. Clin. Chem. 57:1415-23
75. Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjærg-Hansen A. 2010. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies andmeta-analyses. J. Am. Coll. Cardiol. 55:2833-42
76. Naoumova RP, Tosi I, Patel D, Neuwirth C, Horswell SD, et al. 2005. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler. Thromb. Vasc. Biol. 25:2654-60
77. Hopkins PN, Defesche J, Fouchier SW, Bruckert E, Luc G, et al. 2015. Characterization of autosomal dominant hypercholesterolemia caused by PCSK9 gain of function mutations and its specific treatment with alirocumab, a PCSK9 monoclonal antibody. Circ. Cardiovasc. Genet. 8:823-31
78. Alves AC, Etxebarria A, Medeiros AM, Benito-Vicente A, Thedrez A, et al. 2015. Characterization of the first PCSK9 gain of function homozygote. J. Am. Coll. Cardiol. 66:2152-54
79. Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. 2007. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 193:445-48
80. Kühnast S, van der Hoorn JWA, Pieterman EJ, van den Hoek AM, Sasiela WJ, et al. 2014. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J. Lipid Res. 55:2103-12
81. Ni YG, Di Marco S, Condra JH, Peterson LB, Wang W, et al. 2011. A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J. Lipid Res. 52:78-86
82. Zhang L, McCabe T, Condra JH, Ni YG, Peterson LB, et al. 2012. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes. Int. J. Biol. Sci. 8:310-27
83. Lipovsek D. 2011. Adnectins: engineered target-binding protein therapeutics. Protein Eng. Des. Sel. 24:3-9
84. Mitchell T, Chao G, Sitkoff D, Lo F, Monshizadegan H, et al. 2014. Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering. J. Pharmacol. Exp. Ther. 350:412-24
85. Stein EA, Kasichayanula S, Turner T, Kranz T, Arumugam U, et al. 2014. LDL cholesterol reduction with BMS-962476, an adnectin inhibitor of PCSK9: results of a single ascending dose study. J. Am. Coll. Cardiol. 63:A1372
86. Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, et al. 2008. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. PNAS 105:11915-20
87. LeeHS, Seok H, LeeDH,HamJ,LeeW,et al. 2015. Abasic pivot substitution harnesses target specificity of RNA interference. Nat. Commun. 6:10154
88. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, Liebow A, Bettencourt BR, et al. 2014. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, Phase 1 trial. Lancet 383:60-68
89. Graham MJ, Lemonidis KM,Whipple CP, Subramaniam A, Monia BP, et al. 2007. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J. Lipid Res. 48:763-67
90. GuptaN, FiskerN, Asselin MC, LindholmM, Rosenbohm C, et al. 2010. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLOS ONE 5:e10682
91. Lindholm MW, Elmen J, Fisker N, Hansen HF, Persson R, et al. 2012. PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol. Ther. 20:376-81
92. McNuttMC,KwonHJ, Chen C, Chen JR,Horton JD, Lagace TA. 2009. Antagonism of secretedPCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J. Biol. Chem. 284:10561-70
93. Alghamdi RH, O'Reilly P, Lu C, Gomes J, Lagace TA, Basak A. 2015. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation. Eur. J. Med. Chem. 92:890-907
94. Du F, Hui Y, Zhang M, Linton MF, Fazio S, Fan D. 2011. Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein. J. Biol. Chem. 286:43054-61
95. Zhang Y, Eigenbrot C, Zhou L, Shia S, LiW, et al. 2014. Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor. J. Biol. Chem. 289:942-55
96. Schroeder CI, Swedberg JE, Withka JM, Rosengren KJ, Akcan M, et al. 2014. Design and synthesis of truncated EGF-A peptides that restore LDL-R recycling in the presence of PCSK9 in vitro. Chem. Biol. 21:284-94
97. Lo Surdo P, Bottomley MJ, Calzetta A, Settembre EC, Cirillo A, et al. 2011. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. EMBO Rep. 12:1300-5
98. Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, et al. 2012. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl. J. Med. 366:1108-18
99. Koren MJ, Kereiakes D, Pourfarzib R, Winegar D, Banerjee P, et al. 2015. Effect of PCSK9 inhibition by alirocumab on lipoprotein particle concentrations determined by nuclear magnetic resonance spectroscopy. J. Am. Heart. Assoc. 4:e002224
100. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. 2012. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J. Am. Coll. Cardiol. 59:2344-53
101. Dias CS, Shaywitz AJ, Wasserman SM, Smith BP,Gao B, et al. 2012. Effects of AMG145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascendingdose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J. Am. Coll. Cardiol. 60:1888-98
102. Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, et al. 2015. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann. Intern. Med. 163:40-51
103. Li C, Lin L, Zhang W, Zhou L, Wang H, et al. 2015. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials. J. Am. Heart. Assoc. 4:e001937
104. Zhang XL, Zhu QQ, Zhu L, Chen JZ, Chen QH, et al. 2015. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 13:123
105. Lipinski MJ, Benedetto U, Escarcega RO, Biondi-Zoccai G, Lhermusier T, et al. 2016. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Eur. Heart. J. 37:536-45
106. Kolodziejczak M, Navarese EP. 2016. Role ofPCSK9antibodies in cardiovascular disease: critical considerations of mortality and neurocognitive findings from the current literature. Atherosclerosis 247:189-92
107. Sahebkar A, Di Giosia P, Stamerra CA, Grassi D, Pedone C, et al. 2016. Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms. Br. J. Clin. Pharmacol. 81:1175-90
108. Desai NR, Sabatine MS. 2015. PCSK9 inhibition in patients with hypercholesterolemia. Trends Cardiovasc. Med. 25:567-74
109. Giugliano RP, Sabatine MS. 2015. Are PCSK9 inhibitors the next breakthrough in the cardiovascular field J. Am. Coll. Cardiol. 65:2638-51
110. Bergeron N, Phan BA, Ding Y, Fong A, Krauss RM. 2015. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Circulation 132:1648-66
111. Farnier M. 2015. An evaluation of alirocumab for the treatment of hypercholesterolemia. Expert Rev. Cardiovasc. Ther. 13:1307-23
112. Roth EM. 2016. Alirocumab for hyperlipidemia: ODYSSEY Phase III clinical trial results and US FDA approval indications. Future Cardiol. 12:115-28
113. Ballantyne CM, Neutel J, Cropp A, Duggan W, Wang EQ, et al. 2015. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebocontrolled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am. J. Cardiol. 115:1212-21
114. Raal F, Scott R, Somaratne R, Bridges I, Li G, et al. 2012. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 126:2408-17
115. Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, et al. 2015. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 385:331-40
116. Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, et al. 2015. ODYSSEY FHI and FHII: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur. Heart. J. 36:2996-3003
117. Raal FJ,Honarpour N, Blom DJ, HovinghGK, Xu F, et al. 2015. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebocontrolled trial. Lancet 385:341-50
118. Hoe E, Hegele RA. 2015. Lipid management in diabetes with a focus on emerging therapies. Can. J. Diabetes 39:S183-90
119. Sattar N, Preiss D, Robinson JG, Djedjos CS, Elliott M, et al. 2016. Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes Endocrinol. 4:403-10
120. Mancini GB, Tashakkor AY, Baker S, Bergeron J, Fitchett D, et al. 2013. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian WorkingGroup Consensus update. Can. J. Cardiol. 29:1553-68
121. Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, et al. 2014. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled Phase 3 clinical trial of evolocumab. J. Am. Coll. Cardiol. 63:2541-48
122. Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, et al. 2015. Efficacy and safety of alirocumab versus ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J. Clin. Lipidol. 9:758-69
123. Sabatine MS, Giugliano RP, Keech A, Honarpour N, Wang H, et al. 2016. Rationale and design of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk trial. Am. Heart J. 173:94-101
124. Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, et al. 2014. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am. Heart J. 168:682-89
125. Lepor NE,Kereiakes DJ. 2015. The PCSK9 inhibitors: a novel therapeutic target enters clinical practice. Am. Health Drug Benefits 8:483-89
126. Tice JA, Kazi DS, Pearson SD. 2016. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for treatment of high cholesterol levels: effectiveness and value. JAMA Intern. Med. 176:107-8
127. Puri R, Nissen SE, Somaratne R, Cho L, Kastelein JJP, et al. 2016. Impact of PCSK9 inhibition on coronary atheroma progression: rationale and design of GLAGOV (Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound). Am. Heart J. 176:83-92
128. Robinson JG, Heistad DD, Fox KA. 2015. Atherosclerosis stabilization with PCSK-9 inhibition: an evolving concept for cardiovascular prevention. Atherosclerosis 243:593-97
129. Syed GH, Tang H, Khan M, Hassanein T, Liu J, Siddiqui A. 2014. Hepatitis C virus stimulates lowdensity lipoprotein receptor expression to facilitate viral propagation. J. Virol. 88:2519-29
130. Preiss D, Seshasai SR,Welsh P, Murphy SA,Ho JE, et al. 2011. Risk of incident diabetes with intensivedose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305:2556-64